In order to determine whether the increase in EGFR signalling observed in FLCN−/− cell lines is also present in vivo, we examined pAKT, pERK and pSTAT3 expression in a genetically engineered mouse model of BHD kidney cancer (Flcnflox/flox/Sglt2-Cre mouse model40) and in the renal tumours of patients with BHD disease. The gene discussed is EGFR; the disease is kidney neoplasm.